MedTrace Logo

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

NCT05826600 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-04-24

No results posted yet for this study

Summary

The main purpose of the dose escalation phase of the study is to determine the safety of different doses of OMX-0407.

The dose expansion (phase Ib) part of the study will evaluate efficacy, safety and tolerability at a dose determined in the dose escalation,

Conditions

Interventions

DRUG

OMX-0407

Dose escalation, Dose expansion

Sponsors & Collaborators

  • iOmx Therapeutics AG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-30
Primary Completion
2026-04-02
Completion
2026-04-02

Countries

  • Belgium
  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05826600 on ClinicalTrials.gov